ALL-RISE and FAST III are shared as noninferiority trials suggesting angiography-based physiology can match wire-based FFR for intermediate lesions, with reported procedural efficiencies like less contrast and shorter fluoroscopy time.
ALL-RISE trial: FFRangio demonstrated non-inferior 1-year MACE rate compared to conventional pressure wire-based assessment for intermediate coronary lesions, with less contrast volume and shorter fluoroscopy and procedure times.
FAST III trial: In patients with intermediate coronary lesions, vFFR-guided revascularization strategy was non-inferior to FFR-guided approach for the 1-year risk of death, MI, or unplanned revascularization.
I think its time to move away from wire based physiological assessment to much better methods available
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare